BioScrip Inc (BIOS) Releases Earnings Results, Misses Expectations By $-0.05 EPS

BioScrip Inc (BIOS) reported quarterly earnings results on Monday, Aug-8-2016. The company reported $-0.14 earnings per share for the quarter, missing the analyst consensus estimate by $-0.05. Analysts had a consensus of $-0.09. The company posted revenue of $232.50 million in the period, compared to analysts expectations of $227.52 million. The company’s revenue was down -11.4% compared to the same quarter last year.

BioScrip Inc opened for trading at $2.59 and hit $2.69 on the upside on Friday, eventually ending the session at $2.66, with a gain of 2.31% or 0.06 points. The heightened volatility saw the trading volume jump to 7,52,196 shares. Company has a market cap of $183 M.

In a different news, on Jun 20, 2016, R Carter Pate (director) purchased 25,000 shares at $2.50 per share price. According to the SEC, on Aug 19, 2015, David W Golding (director) purchased 20,000 shares at $1.54 per share price. On Mar 17, 2015, Richard M Smith (CEO) purchased 5,000 shares at $4.27 per share price, according to the Form-4 filing with the securities and exchange commission.

BioScrip Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians hospital systems skilled nursing facilities healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy respiratory therapy and the provision of durable medical equipment products and services. Its PBM Services segment consists of integrated PBM services which primarily consists of discount card programs that provide alternative for individuals who may be uninsured underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products services and condition-specific clinical management programs for health conditions such as gastrointestinal abnormalities infectious diseases and others.

BioScrip Inc

Leave a Reply

BioScrip Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioScrip Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.